Research Progress on the osteogenic differentiation of ADSCs induced by epimedium in the prevention and treatment of osteoporosis

Osteoporosis (OP) is a chronic, systemic bone disease. With the arrival of the aging society, the research on the prevention and treatment of this disease is increasing. Finding effective drugs to induce osteogenesis and differentiation of adipose-derived mesenchymal stem cells (ADSCs) is currently...

Full description

Saved in:
Bibliographic Details
Main Authors: Hai-Quan LIU, Mei-Jian-Zong WU, Zu-Yu MENG
Format: Article
Language:zho
Published: Editorial Office of New Medicine 2023-10-01
Series:Yixue xinzhi zazhi
Subjects:
Online Access:https://yxxz.whuznhmedj.com/futureApi/storage/attach/2310/XLe2PMc38ZMiLCy3rWw9RFGGg1RSJ2ngw1LbtmAR.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849219935147917312
author Hai-Quan LIU
Mei-Jian-Zong WU
Zu-Yu MENG
author_facet Hai-Quan LIU
Mei-Jian-Zong WU
Zu-Yu MENG
author_sort Hai-Quan LIU
collection DOAJ
description Osteoporosis (OP) is a chronic, systemic bone disease. With the arrival of the aging society, the research on the prevention and treatment of this disease is increasing. Finding effective drugs to induce osteogenesis and differentiation of adipose-derived mesenchymal stem cells (ADSCs) is currently a more focused strategy for prevention and treatment of OP. Peroxisome proliferator-activated receptor gamma (PPARγ) is the key protein of adipocyte differentiation. Studies have confirmed that the intervention of epimedium on bone marrow mesenchymal stem cells (BMSCs) can inhibit the expression of PPARγ, thus inhibits adipogenic differentiation of BMSCs and promotes their osteogenic differentiation. Hippo signal pathway controls the activity of YAP/TAZ transcriptional coactivator through kinase cascade and inhibiting PPARγ, which can inhibit ADSCs from differentiating into adipocytes. Ajuba is an important regulator of adipogenic differentiation of cells and a new PPARγ interacting proteins which can limit the activity of Hippo signaling pathway during cell proliferation. Epimedium has unique advantages in the prevention and treatment of OP. Previous studies found that epimedium can promote the osteogenic differentiation of ADSCs and inhibit their lipogenic differentiation. PPARγ, Hippo pathway and Ajuba are closely related in the pathogenesis of OP. According to previous research, this paper is purposed to review the mechanism of epimedium in ADSCs for the prevention and treatment of OP, and to provide a reference for the development of new clinical drugs.
format Article
id doaj-art-3ea50d8cd8fd436aac10e2aa5df0c14f
institution Kabale University
issn 1004-5511
language zho
publishDate 2023-10-01
publisher Editorial Office of New Medicine
record_format Article
series Yixue xinzhi zazhi
spelling doaj-art-3ea50d8cd8fd436aac10e2aa5df0c14f2024-12-25T10:11:12ZzhoEditorial Office of New MedicineYixue xinzhi zazhi1004-55112023-10-0133538138810.12173/j.issn.1004-5511.2023030446415Research Progress on the osteogenic differentiation of ADSCs induced by epimedium in the prevention and treatment of osteoporosisHai-Quan LIUMei-Jian-Zong WUZu-Yu MENGOsteoporosis (OP) is a chronic, systemic bone disease. With the arrival of the aging society, the research on the prevention and treatment of this disease is increasing. Finding effective drugs to induce osteogenesis and differentiation of adipose-derived mesenchymal stem cells (ADSCs) is currently a more focused strategy for prevention and treatment of OP. Peroxisome proliferator-activated receptor gamma (PPARγ) is the key protein of adipocyte differentiation. Studies have confirmed that the intervention of epimedium on bone marrow mesenchymal stem cells (BMSCs) can inhibit the expression of PPARγ, thus inhibits adipogenic differentiation of BMSCs and promotes their osteogenic differentiation. Hippo signal pathway controls the activity of YAP/TAZ transcriptional coactivator through kinase cascade and inhibiting PPARγ, which can inhibit ADSCs from differentiating into adipocytes. Ajuba is an important regulator of adipogenic differentiation of cells and a new PPARγ interacting proteins which can limit the activity of Hippo signaling pathway during cell proliferation. Epimedium has unique advantages in the prevention and treatment of OP. Previous studies found that epimedium can promote the osteogenic differentiation of ADSCs and inhibit their lipogenic differentiation. PPARγ, Hippo pathway and Ajuba are closely related in the pathogenesis of OP. According to previous research, this paper is purposed to review the mechanism of epimedium in ADSCs for the prevention and treatment of OP, and to provide a reference for the development of new clinical drugs.https://yxxz.whuznhmedj.com/futureApi/storage/attach/2310/XLe2PMc38ZMiLCy3rWw9RFGGg1RSJ2ngw1LbtmAR.pdfepimediumosteoporosisadscsosteogenic differentiationpparγ/hippo/ajuba pathway
spellingShingle Hai-Quan LIU
Mei-Jian-Zong WU
Zu-Yu MENG
Research Progress on the osteogenic differentiation of ADSCs induced by epimedium in the prevention and treatment of osteoporosis
Yixue xinzhi zazhi
epimedium
osteoporosis
adscs
osteogenic differentiation
pparγ/hippo/ajuba pathway
title Research Progress on the osteogenic differentiation of ADSCs induced by epimedium in the prevention and treatment of osteoporosis
title_full Research Progress on the osteogenic differentiation of ADSCs induced by epimedium in the prevention and treatment of osteoporosis
title_fullStr Research Progress on the osteogenic differentiation of ADSCs induced by epimedium in the prevention and treatment of osteoporosis
title_full_unstemmed Research Progress on the osteogenic differentiation of ADSCs induced by epimedium in the prevention and treatment of osteoporosis
title_short Research Progress on the osteogenic differentiation of ADSCs induced by epimedium in the prevention and treatment of osteoporosis
title_sort research progress on the osteogenic differentiation of adscs induced by epimedium in the prevention and treatment of osteoporosis
topic epimedium
osteoporosis
adscs
osteogenic differentiation
pparγ/hippo/ajuba pathway
url https://yxxz.whuznhmedj.com/futureApi/storage/attach/2310/XLe2PMc38ZMiLCy3rWw9RFGGg1RSJ2ngw1LbtmAR.pdf
work_keys_str_mv AT haiquanliu researchprogressontheosteogenicdifferentiationofadscsinducedbyepimediuminthepreventionandtreatmentofosteoporosis
AT meijianzongwu researchprogressontheosteogenicdifferentiationofadscsinducedbyepimediuminthepreventionandtreatmentofosteoporosis
AT zuyumeng researchprogressontheosteogenicdifferentiationofadscsinducedbyepimediuminthepreventionandtreatmentofosteoporosis